Abstract: Disclosed herein are an anti-HER2 affibody and a switch molecule including a cotinine-conjugated anti-HER2 affibody. When applied in combination with Cot-sCART, the cotinine-conjugated anti-HER2 affibody reacts with HER2-positive cells to induce immune cell activity, thereby finding advantageous applications as switch molecules in sCART therapeutic agents.

Abstract: The present invention relates to an antibody or antigen-binding fragment thereof that targets cotinine, a chimeric antigen receptor comprising same, and uses thereof. The antibody of the present invention is an antibody that specifically binds to cotinine, and in particular, an antibody that binds more specifically to the S-isomer of cotinine than to the R-isomer thereof. In addition, the antibody has very low homology and a unique sequence, compared to the CDR sequences of conventional cotinine target antibodies. Cells expressing a chimeric antigen receptor comprising the anti-cotinine antibody or antigen-binding fragment of the present invention bind to a cotinine-conjugated switch and respond to a target cell line, thereby inducing immune cell activity. Therefore, the antibody or antigen-binding fragment thereof of the present invention can be used to suppress immune side effects due to overactivation of T cells through cotinine-mediated activation regulation of chimeric antigen receptor effector cells.

Abstract: Disclosed herein are a novel antibody and an antigen binding fragment thereof that targets CD30 to treat cancer, a chimeric antigen receptor, and a use thereof. The antibody, which binds specifically to CD30 that is highly expressed in cancer cells (specifically blood cancer), is very low in sequence homology with the CDR sequences of conventional CD30 targeting antibodies and thus has a unique sequence. Cells that express the chimeric antigen receptor including the anti-CD30 antibody or the antigen binding fragment responds to CD30-expressing positive cells to induce immune cell activity, thus finding advantageous applications as a CAR-immune cell product.

Abstract: Disclosed are a novel antibody specifically binding to the tumor-immunosuppressant, TIGIT (T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif [ITIM] domain) or an antigen-binding fragment thereof, a nucleic acid encoding the antibody or the antigen-binding fragment thereof, a vector and a host cell including the nucleic acid, a method for producing the antibody or the antigen-binding fragment thereof, a pharmaceutical composition containing the antibody or the antigen-binding fragment thereof as an active ingredient, and uses of the pharmaceutical composition. The antibody specifically binding to TIGIT or the antigen-binding fragment thereof and the pharmaceutical composition containing the same as an active ingredient are preferably used for the treatment of cancer or tumors.

Abstract: Disclosed herein are an anti-HER2 affibody and a switch molecule including a cotinine-conjugated anti-HER2 affibody. When applied in combination with Cot-sCART, the cotinine-conjugated anti-HER2 affibody reacts with HER2-positive cells to induce immune cell activity, thereby finding advantageous applications as switch molecules in sCART therapeutic agents.

Abstract: Disclosed are a novel antibody specifically binding to the tumor-immunosuppressant, TIGIT (T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif [ITIM] domain) or an antigen-binding fragment thereof, a nucleic acid encoding the antibody or the antigen-binding fragment thereof, a vector and a host cell including the nucleic acid, a method for producing the antibody or the antigen-binding fragment thereof, a pharmaceutical composition containing the antibody or the antigen-binding fragment thereof as an active ingredient, and uses of the pharmaceutical composition. The antibody specifically binding to TIGIT or the antigen-binding fragment thereof and the pharmaceutical composition containing the same as an active ingredient are preferably used for the treatment of cancer or tumors.

Abstract: An environmental sensor for an electronic device includes a substrate, a first sensing unit having a first sensor electrode disposed on the substrate, a second sensing unit having a second sensor electrode disposed on the substrate, an insulating layer covering the first sensor electrode, and a cover that is disposed over the first and second sensor electrodes, the cover including at least one hole through which chemical particles pass. The first and second sensing units each sense one of a capacitance-change due to the chemical particles that pass through the hole and then adhere to the insulating layer located on the first sensor electrode and a resistance-change due to the chemical particles that pass through the hole and then adhere to the second sensor electrode.

Abstract: The present invention relates to HER2 (Human Epidermal Growth Factor Receptor 2) antibodies to prevent or treat cancers. The antibodies of the invention binds specifically to HER2 over-expressed in cancer cells (particularly, breast cancer and stomach cancer cells), specifically to an epitope on HER2 being different from epitope for trastuzumab. The CDR sequences of the present antibodies exhibit low similarity to CDR sequences of publicly known HER2 antibodies, addressing that the CDR sequences are unique. The antibodies of the present invention in combination with trastuzumab kill cancer cells with significantly enhanced cytotoxicity and therefore very effective in therapy of cancer (particularly, breast cancer and stomach cancer). Without wishing to be bound by theory, the enhanced efficacies of the combined therapy would address that the antibodies of the present invention bind to epitope on HER2 being different from epitope for trastuzumab, and inhibit HER2 in a cooperative manner with trastuzumab.

Abstract: An environmental sensor for an electronic device includes a substrate, a first sensing unit having a first sensor electrode disposed on the substrate, a second sensing unit having a second sensor electrode disposed on the substrate, an insulating layer covering the first sensor electrode, and a cover that is disposed over the first and second sensor electrodes, the cover including at least one hole through which chemical particles pass. The first and second sensing units each sense one of a capacitance-change due to the chemical particles that pass through the hole and then adhere to the insulating layer located on the first sensor electrode and a resistance-change due to the chemical particles that pass through the hole and then adhere to the second sensor electrode.

Abstract: Provided is a display device, including: a first substrate including a display area and a non-display area adjacent to the display area; a display unit on the first substrate at the display area and configured to display an image; a display wiring on the first substrate at the non-display area and coupled to the display unit; a second substrate on the first substrate with the display unit and the display wiring therebetween; a touch unit on the second substrate, corresponding to the display unit, and configured to recognize a touch; a touch wiring on the second substrate at the non-display area and coupled to the touch unit; and an anti-noise electrode between the display wiring and the touch wiring at the non-display area.

Abstract: The present invention relates to HER2 (Human Epidermal Growth Factor Receptor 2) antibodies to prevent or treat cancers. The antibodies of the invention binds specifically to HER2 over-expressed in cancer cells (particularly, breast cancer and stomach cancer cells), specifically to an epitope on HER2 being different from epitope for trastuzumab. The CDR sequences of the present antibodies exhibit low similarity to CDR sequences of publicly known HER2 antibodies, addressing that the CDR sequences are unique. The antibodies of the present invention in combination with trastuzumab kill cancer cells with significantly enhanced cytotoxicity and therefore very effective in therapy of cancer (particularly, breast cancer and stomach cancer). Without wishing to be bound by theory, the enhanced efficacies of the combined therapy would address that the antibodies of the present invention bind to epitope on HER2 being different from epitope for trastuzumab, and inhibit HER2 in a cooperative manner with trastuzumab.

Abstract: A lens has a refractive index of n, and includes a base, a first curved circumferential surface extending from the base, a curved center-edge surface extending from the first curved circumferential surface, and a curved centermost surface extending from the curved center-edge surface. The base includes a groove for receiving a light emitting chip. A distance from a center of the base to a point of the curved center-edge surface is shorter than the radius of curvature for the point of the curved center-edge surface. The curved centermost surface has a concave shape with respect to the base. The lens satisfies A1+A2<90+sin?1(1/n), where A1 an obtuse angle between a main axis and a tangent line of the curved centermost surface, and A2 is an acute angle between a straight line linking the center of the base to the point of the curved centermost surface and the main axis.

Abstract: Provided is a display device, including: a first substrate including a display area and a non-display area adjacent to the display area; a display unit on the first substrate at the display area and configured to display an image; a display wiring on the first substrate at the non-display area and coupled to the display unit; a second substrate on the first substrate with the display unit and the display wiring therebetween; a touch unit on the second substrate, corresponding to the display unit, and configured to recognize a touch; a touch wiring on the second substrate at the non-display area and coupled to the touch unit; and an anti-noise electrode between the display wiring and the touch wiring at the non-display area.

Abstract: A transparent display panel includes a first substrate, a second substrate facing the first substrate, and a liquid crystal layer between the first substrate and the second substrate. The first substrate includes a gate line set including two gate lines; a data line set including two data lines; a pixel electrode in a unit pixel area; a switching element electrically connected to a gate line, a data line and the pixel electrode; and a black matrix on the gate line set and the data line set.

Abstract: A lens for a light emitting diode is formed with a material having a refractive index of n, and the lens includes a base, a first curved circumferential surface extending from the base, a curved center-edge surface extending from the first curved circumferential surface, and a curved centermost surface extending from the curved center-edge surface. The base includes a groove for receiving a light emitting chip therein. In the lens, a distance from a center of the base to a point of the curved center-edge surface is always shorter than the radius of curvature for the point of the curved center-edge surface. The curved centermost surface has a concave shape with respect to the base.

Abstract: A light guide for converting a dot light source or a linear light source into a planar light source, and the light guide includes a light emitting surface and a reflection surface facing the light emitting surface and having a plurality of reflection patterns, wherein a width of the reflection patterns is less than 10 ?m.

Abstract: A lens has a refractive index of n, and includes a base, a first curved circumferential surface extending from the base, a curved center-edge surface extending from the first curved circumferential surface, and a curved centermost surface extending from the curved center-edge surface. The base includes a groove for receiving a light emitting chip. A distance from a center of the base to a point of the curved center-edge surface is shorter than the radius of curvature for the point of the curved center-edge surface. The curved centermost surface has a concave shape with respect to the base. The lens satisfies A1+A2<90+sin?1(1/n), where A1 an obtuse angle between a main axis and a tangent line of the curved centermost surface, and A2 is an acute angle between a straight line linking the center of the base to the point of the curved centermost surface and the main axis.

Abstract: A lens for a light emitting diode is formed with a material having a refractive index of n, and the lens includes a base, a first curved circumferential surface extending from the base, a curved center-edge surface extending from the first curved circumferential surface, and a curved centermost surface extending from the curved center-edge surface. The base includes a groove for receiving a light emitting chip therein. In the lens, a distance from a center of the base to a point of the curved center-edge surface is always shorter than the radius of curvature for the point of the curved center-edge surface. The curved centermost surface has a concave shape with respect to the base.

Abstract: The present invention provides an optical film composite that includes a linear, reflective polarizing film; a first polymeric substrate layer having birefringence, which is placed on the reflective polarizing film; and a second polymeric substrate layer placed beneath the reflective polarizing film, wherein the optical axis of the first polymeric substrate layer is oriented with respect to the transmission axis of the reflective polarizing film to have of 0° to 25° of an angular difference between the axes. The optical film composite can be employed in LCD devices to improve optical performance.

Abstract: A method of driving a light source includes converting a reference luminance value of the light source to a first just noticeable difference (JND) value. The JND value represents a minimum noticeable difference between two stimuli. A target luminance value lower than the reference luminance value is determined using the first JND value. A first driving signal applied to the light source is generated using the target luminance value so that a user may not notice a luminance change when a luminance value of a light source is decreased in order to decrease power consumption of a display apparatus.